BioSpace News Archive

On track to initiate the OPTION 2 trial by the end of Q2 2020 OPTION 2 trial to compare efficacy of standard of care to 2.2 and 4.4 gram doses of MS1819 in enteric capsules Trial completion and top-line data expected in Q1 2021 NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the Company rece

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its first quarter 2020 on Wednesday, May 6, 2020. Management will host a conference call to review the results at 8:30 AM ET on the same day. The conference call may be accessed by dialing (877) 312-7507 from the U.S. and Canada or (631) 813-4828 from international locat

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today upcoming presentations demonstrating the broad applicability of its in vivo gene therapy and nuclease-free gene editing platform across multiple disease areas. Presentations will also include mechanistic data further characterizing Homology’s novel AAVHSC vectors and details on the commercial manufacturing process and internal GMP production capabilities a

End of Phase 2 FDA meeting scheduled to discuss the path forward for IFX-1 in Hidradenitis Suppurativa Initial promising results reported in Pyoderma Gangraenosum Part 1 of adaptive randomized trial in severe COVID-19 pneumonia fully enrolled Executed clinical collaboration agreement in oncology with Merck & Co, Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada) Senior executives hired for key positions Cash, cash equivalents and financial assets were €115.8 million as o

- Transaction enables Opocrin to become a leading global producer of active biologics including heparin and heparinoids -

Amplyx Pharmaceuticals , a clinical stage biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that Ciara Kennedy , Ph.D., President and Chief Executive Officer, will participate in a panel discussing fungal pathogens and the emerging

Version 19 offers mechanistic models for assessing maternal-fetal drug risk, developing drug formulations, and optimizing dermal and transdermal drug development

Incyte announced that it will present at the 2020 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2020 at 3:05 p.m. ET..

AJOVY™ is the first and only anti-CGRP treatment with both quarterly and monthly dosing for the preventive treatment of migraine in adults

EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, will present data on its lead therapeutic program for patients with the most severe form of mucopolysaccharidosis type I (MPS I), known as Hurler syndrome, at the 23rd American Society of Gene & Cell Therapy (ASGCT) Annual Meeting on Tuesday, May 12, 2020